A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 90307
NMA SSA Reference Number: SSA/90307/MonH-2023-355207(v1)
Monash Health Local Reference: RES-22-0000-597A
Effective start/end date22/05/2321/05/28